A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc..
Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the United States (Germany, n = 66; United States, n = 106; total, n = 172), we demonstrate that wide-spectrum antibiotics treatment ('high-risk antibiotics') prior to CD19-targeted chimeric antigen receptor (CAR)-T cell therapy is associated with adverse outcomes, but this effect is likely to be confounded by an increased pretreatment tumor burden and systemic inflammation in patients pretreated with high-risk antibiotics. To resolve this confounding effect and gain insights into antibiotics-masked microbiome signals impacting CAR-T efficacy, we focused on the high-risk antibiotics non-exposed patient population. Indeed, in these patients, significant correlations were noted between pre-CAR-T infusion Bifidobacterium longum and microbiome-encoded peptidoglycan biosynthesis, and CAR-T treatment-associated 6-month survival or lymphoma progression. Furthermore, predictive pre-CAR-T treatment microbiome-based machine learning algorithms trained on the high-risk antibiotics non-exposed German cohort and validated by the respective US cohort robustly segregated long-term responders from non-responders. Bacteroides, Ruminococcus, Eubacterium and Akkermansia were most important in determining CAR-T responsiveness, with Akkermansia also being associated with pre-infusion peripheral T cell levels in these patients. Collectively, we identify conserved microbiome features across clinical and geographical variations, which may enable cross-cohort microbiome-based predictions of outcomes in CAR-T cell immunotherapy.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Nature medicine - 29(2023), 4 vom: 13. Apr., Seite 906-916 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD19 |
|---|
| Anmerkungen: |
Date Completed 21.04.2023 Date Revised 21.11.2023 published: Print-Electronic CommentIn: Nat Med. 2023 Apr;29(4):785-786. - PMID 36973411 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-023-02234-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354204793 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354204793 | ||
| 003 | DE-627 | ||
| 005 | 20231226061720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-023-02234-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354204793 | ||
| 035 | |a (NLM)36914893 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Stein-Thoeringer, Christoph K |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.04.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Nat Med. 2023 Apr;29(4):785-786. - PMID 36973411 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature America, Inc. | ||
| 520 | |a Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the United States (Germany, n = 66; United States, n = 106; total, n = 172), we demonstrate that wide-spectrum antibiotics treatment ('high-risk antibiotics') prior to CD19-targeted chimeric antigen receptor (CAR)-T cell therapy is associated with adverse outcomes, but this effect is likely to be confounded by an increased pretreatment tumor burden and systemic inflammation in patients pretreated with high-risk antibiotics. To resolve this confounding effect and gain insights into antibiotics-masked microbiome signals impacting CAR-T efficacy, we focused on the high-risk antibiotics non-exposed patient population. Indeed, in these patients, significant correlations were noted between pre-CAR-T infusion Bifidobacterium longum and microbiome-encoded peptidoglycan biosynthesis, and CAR-T treatment-associated 6-month survival or lymphoma progression. Furthermore, predictive pre-CAR-T treatment microbiome-based machine learning algorithms trained on the high-risk antibiotics non-exposed German cohort and validated by the respective US cohort robustly segregated long-term responders from non-responders. Bacteroides, Ruminococcus, Eubacterium and Akkermansia were most important in determining CAR-T responsiveness, with Akkermansia also being associated with pre-infusion peripheral T cell levels in these patients. Collectively, we identify conserved microbiome features across clinical and geographical variations, which may enable cross-cohort microbiome-based predictions of outcomes in CAR-T cell immunotherapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 650 | 7 | |a Antigens, CD19 |2 NLM | |
| 700 | 1 | |a Saini, Neeraj Y |e verfasserin |4 aut | |
| 700 | 1 | |a Zamir, Eli |e verfasserin |4 aut | |
| 700 | 1 | |a Blumenberg, Viktoria |e verfasserin |4 aut | |
| 700 | 1 | |a Schubert, Maria-Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Mor, Uria |e verfasserin |4 aut | |
| 700 | 1 | |a Fante, Matthias A |e verfasserin |4 aut | |
| 700 | 1 | |a Schmidt, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Hayase, Eiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hayase, Tomo |e verfasserin |4 aut | |
| 700 | 1 | |a Rohrbach, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Chia-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a McDaniel, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Flores, Ivonne |e verfasserin |4 aut | |
| 700 | 1 | |a Gaiser, Rogier |e verfasserin |4 aut | |
| 700 | 1 | |a Edinger, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Wolff, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Heidenreich, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Strati, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Ranjit |e verfasserin |4 aut | |
| 700 | 1 | |a Chihara, Dai |e verfasserin |4 aut | |
| 700 | 1 | |a Fayad, Luis E |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Sairah |e verfasserin |4 aut | |
| 700 | 1 | |a Iyer, Swaminathan P |e verfasserin |4 aut | |
| 700 | 1 | |a Steiner, Raphael E |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Preetesh |e verfasserin |4 aut | |
| 700 | 1 | |a Nastoupil, Loretta J |e verfasserin |4 aut | |
| 700 | 1 | |a Westin, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Arora, Reetakshi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Michael L |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Menges, Meghan |e verfasserin |4 aut | |
| 700 | 1 | |a Hidalgo-Vargas, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Reid, Kayla |e verfasserin |4 aut | |
| 700 | 1 | |a Dreger, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |e verfasserin |4 aut | |
| 700 | 1 | |a Locke, Frederick L |e verfasserin |4 aut | |
| 700 | 1 | |a Davila, Marco L |e verfasserin |4 aut | |
| 700 | 1 | |a Champlin, Richard E |e verfasserin |4 aut | |
| 700 | 1 | |a Flowers, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Shpall, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Poeck, Hendrik |e verfasserin |4 aut | |
| 700 | 1 | |a Neelapu, Sattva S |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Subklewe, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Jain, Michael D |e verfasserin |4 aut | |
| 700 | 1 | |a Jenq, Robert R |e verfasserin |4 aut | |
| 700 | 1 | |a Elinav, Eran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 29(2023), 4 vom: 13. Apr., Seite 906-916 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:4 |g day:13 |g month:04 |g pages:906-916 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-023-02234-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 4 |b 13 |c 04 |h 906-916 | ||